Aquamarine Financial (ORMP) discloses 6.04% Oramed ownership in 13G/A

Rhea-AI Filing Summary

Aquamarine Financial (Cayman) Ltd reports beneficial ownership of 2,512,175 shares of Oramed Pharmaceuticals Inc. common stock, representing 6.04% of the class as of June 30, 2026. Aquamarine holds sole voting and sole dispositive power over all reported shares and no shared power.

Key Figures

Beneficially owned shares: 2,512,175 shares Ownership percentage: 6.04% Sole voting power: 2,512,175 shares +2 more

5 metrics

Beneficially owned shares 2,512,175 shares Common stock beneficially owned by Aquamarine Financial (Cayman) Ltd

Ownership percentage 6.04% Percent of Oramed Pharmaceuticals Inc. common stock class

Sole voting power 2,512,175 shares Shares over which Aquamarine has sole power to vote

Sole dispositive power 2,512,175 shares Shares over which Aquamarine has sole power to dispose

Signature date 08/14/2026 Date the ownership report was signed by Director David Mungall

Key Terms

beneficially owned, Sole dispositive power, Sole voting power, Schedule 13G/A

4 terms

beneficially owned financial

"Item 4. | Ownership (a) | Amount beneficially owned: 2,512,175"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole dispositive power financial

"Sole Dispositive Power 2,512,175.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Sole voting power financial

"Sole Voting Power 2,512,175.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

Schedule 13G/A regulatory

"form_type: "SCHEDULE 13G/A""

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

FAQ

What percentage of Oramed Pharmaceuticals (ORMP) does Aquamarine Financial own?

Aquamarine Financial (Cayman) Ltd reports owning 6.04% of Oramed Pharmaceuticals Inc. common stock. This stake reflects 2,512,175 shares with sole voting and dispositive power over the entire reported position.

How many Oramed (ORMP) shares are beneficially owned by Aquamarine Financial?

Aquamarine Financial (Cayman) Ltd beneficially owns 2,512,175 shares of Oramed Pharmaceuticals Inc. common stock. These shares represent 6.04% of the class and are held with sole voting and sole dispositive authority.

Does Aquamarine Financial share voting power over its ORMP shares?

No. Aquamarine Financial (Cayman) Ltd reports sole voting power over 2,512,175 shares and zero shared voting power. It also has sole dispositive power over the same number of Oramed Pharmaceuticals Inc. shares.

What kind of SEC filing is this for Oramed (ORMP)?

This is an Amendment No. 1 to Schedule 13G, reporting Aquamarine Financial (Cayman) Ltd’s beneficial ownership in Oramed Pharmaceuticals Inc., including 2,512,175 shares and a 6.04% ownership stake with sole voting and dispositive power.

Who signed the Oramed (ORMP) Schedule 13G/A for Aquamarine Financial?

The filing was signed by /s/ David Mungall as Director of Aquamarine Financial (Cayman) Ltd. The signature date reported is 08/14/2026, confirming the ownership disclosure as of that time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 11:53 AM Accepted by SEC EDGAR 08/14/2026 - 11:52 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

ORAMED PHARMACEUTICALS INC.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

68403P203

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 68403P203

1

Names of Reporting Persons

Aquamarine Financial (Cayman) Ltd

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,512,175.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,512,175.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,512,175.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.04 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ORAMED PHARMACEUTICALS INC.
(b)	Address of issuer's principal executive offices: 1185 Avenue of the Americas, 3rd Fl, New York, New York,10036
Item 2.
(a)	Name of person filing: Aquamarine Financial (Cayman) Ltd
(b)	Address or principal business office or, if none, residence: 23 Lime Tree Bay Avenue, Grand Cayman, Cayman Islands KY1-1002
(c)	Citizenship: Cayman Islands
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 68403P203
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 2,512,175
(b)	Percent of class: 6.04%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 2,512,175
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 2,512,175
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Aquamarine Financial (Cayman) Ltd

Signature:	/s/ David Mungall
Name/Title:	Director
Date:	08/14/2026